Trial Profile
A Phase I/II, Randomized, Safety and Ascending Dose Ranging Study of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Idursulfase (Primary) ; Idursulfase (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions; First in man
- Sponsors Shire; Shire Human Genetic Therapies
- 18 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
- 13 Sep 2014 New trial record